Hansa Biopharma names Donato Spota as new CFO

pharmafile | February 7, 2019 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Swedish firm Hansa Biopharma has appointed Donato Spota as the company’s new Chief Financial Officer (CFO). Spota will succeed current CFO Eva-Maria Joed on 15 May 2019. Joed will continue in the company as Vice president, Finance & Administration, a position in which she will report to Spota.

Spota is a senior executive with more than 30 years’ worth of pharmaceutical industry experience. Prior to Hansa Spota acted as CFO of Swiss firm Basilea Pharmaceutica AG. Spota has been in his previous role for the past five eyars and has worked for Basilea for a total of 16 years.

Søren Tulstrup, President & CEO of Hansa Biopharma, said: “We are very pleased to welcome Donato as our new CFO and a member of our executive team. With his extensive international experience as CFO of a listed, commercial-stage biopharmaceutical company, Donato will be a very valuable addition to our team as we continue the transformation of Hansa Biopharma and grow our operations and organization.”

Prior to his role as CFO at Basilea, Spota held various other senior financial leadership positions. Spota holds a degreein Information Technology from the Swiss Bundesamt für Berufsbildung und Technologie and a Master’s degree in Business Administration from the Hochschule für Wirtschaft und Umwelt.

Related Content

No items found

Latest content